Education
About Us
Working with TipRanks
Follow Us
Silexion Therapeutics (SLXN)
NASDAQ:SLXN
SLXN Stock Chart & Stats
$2.12
-$0.10(-4.76%)
At close: 4:00 PM EST
$2.12
-$0.10(-4.76%)
Day’s Range― - ―
52-Week Range$1.65 - $36.00
Previous CloseN/A
Volume52.80K
Average Volume (3M)50.14K
Market Cap
$5.72M
Enterprise Value-$7.73M
Total Cash (Recent Filing)$9.24M
Total Debt (Recent Filing)$485.00K
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Mar 24, 2026EPS Estimate
-1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.88
Shares Outstanding3,126,642
10 Day Avg. Volume60,134
30 Day Avg. Volume50,136
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)-47.15
Price to Sales (P/S)0.00
P/FCF Ratio-22.34
Enterprise Value/Market Cap-1.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.10K
Enterprise Value/Ebitda1.03
Forecast
1Y Price Target
$9.00Price Target Upside324.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.99
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Strategy And Market ExpansionPlans to pursue both intratumoral and systemic administration and to include overall survival as the primary endpoint broaden the addressable patient population and could enhance the therapy's commercial appeal.
Preclinical EfficacyPreclinical evidence of pan-KRAS inhibition and anti-tumor activity across multiple KRAS mutations and cancer types strengthens confidence in SIL-204's mechanism and clinical potential.
Regulatory ProgressSubmission of a Phase 2/3 regulatory application in Israel and positive feedback from German regulators advances the clinical regulatory pathway for SIL-204 and supports multi-jurisdictional trial initiation.
Bears Say
Financing RequirementsAvailable cash is expected to fund trial initiation only, creating a financing gap that may require additional capital raises and introduce dilution risk for shareholders.
Valuation Impact From DilutionA reduced analyst price target tied to additional shares from a capital raise highlights market concern about dilution and downward pressure on near-term valuation.
Silexion Therapeutics News
SLXN FAQ
What was Silexion Therapeutics’s price range in the past 12 months?
Silexion Therapeutics lowest stock price was $1.65 and its highest was $36.00 in the past 12 months.
What is Silexion Therapeutics’s market cap?
Silexion Therapeutics’s market cap is $5.72M.
When is Silexion Therapeutics’s upcoming earnings report date?
Silexion Therapeutics’s upcoming earnings report date is Mar 24, 2026 which is in 51 days.
How were Silexion Therapeutics’s earnings last quarter?
Silexion Therapeutics released its earnings results on Nov 12, 2025. The company reported -$2.88 earnings per share for the quarter, beating the consensus estimate of -$3.4 by $0.52.
Is Silexion Therapeutics overvalued?
According to Wall Street analysts Silexion Therapeutics’s price is currently Undervalued.
Does Silexion Therapeutics pay dividends?
Silexion Therapeutics does not currently pay dividends.
What is Silexion Therapeutics’s EPS estimate?
Silexion Therapeutics’s EPS estimate is -1.12.
How many shares outstanding does Silexion Therapeutics have?
Silexion Therapeutics has 3,126,642 shares outstanding.
What happened to Silexion Therapeutics’s price movement after its last earnings report?
Silexion Therapeutics reported an EPS of -$2.88 in its last earnings report, beating expectations of -$3.4. Following the earnings report the stock price went up 3.559%.
Which hedge fund is a major shareholder of Silexion Therapeutics?
Currently, no hedge funds are holding shares in SLXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Silexion Therapeutics
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
SLXN Stock 12 Month Forecast
Average Price Target
$9.00
▲(324.53% Upside)